<DOC>
	<DOCNO>NCT01328522</DOCNO>
	<brief_summary>Primary Objective : Assess comparative safety tolerability two SAR153191 ( REGN88 ) drug product single dose administration rheumatoid arthritis patient . Secondary Objective : Assess comparative pharmacokinetic profile two SAR153191 ( REGN88 ) drug product single dose administration rheumatoid arthritis patient .</brief_summary>
	<brief_title>Comparison Safety Pharmacokinetics Two SAR153191 ( REGN88 ) Drug Products Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>The duration study period per subject 5-7 week break follow : - Screening : 1 14 day , - Treatment : 1 day ( 2 overnight stay study site ) , - Follow-up : 5 week dose ( additional outpatient follow-up may schedule depend last result ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion criterion : Diagnosis rheumatoid arthritis ( RA ) &gt; = 3 month duration . Treated minimum 12 week Methotrexate ( MTX ) prior randomization . Treatment must continue stable dose duration study . Exclusion criterion : Autoimmune disease RA . History acute inflammatory joint disease RA . Surgery within 4 week prior screen visit plan elective surgery within next 3 month . Latent active tuberculosis . Fever ( â‰¥38 C ) persistent chronic active recur infection require treatment antibiotic , antiviral , antifungal within 4 week prior screen visit , history frequent recurrent infection . Received administration live ( attenuate ) vaccine within 3 month prior randomization visit ( eg , varicellazoster vaccine , oral polio , rabies ) . Received tuberculosis vaccination within 12 month prior screen Prior therapy Tumor Necrosis Factor ( TNF ) antagonist biologic agent within 3 month prior inclusion . Known latex sensitivity . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>